Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Moti Ramgopal, Dushyantha T Jayaweera, Peter A Leone, Jessica E Matthews, Michael Cupo, Mark R Underwood, Konstantinos Angelis, Brian R Wynne, Deanna Merrill, Christopher Nguyen, Jean van Wyk, Andrew R Zolopa
BACKGROUND: We assessed the efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in a US test-and-treat setting at a secondary 48-week time point of the multicenter, single-arm, phase IIIb STAT study. METHODS: Participants were eligible adults newly diagnosed with human immunodeficiency virus (HIV)-1 and had started once-daily DTG/3TC within 14 days of diagnosis, before laboratory results were available. Antiretroviral therapy (ART) was modified if baseline testing indicated DTG or 3TC resistance, hepatitis B virus (HBV) coinfection, or creatinine clearance <30 mL/min per 1...
March 2023: Open Forum Infectious Diseases